



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6171

Title: TREATMENT OPTIONS IN PATIENTS WITH METASTATIC GASTRIC CANCER: CURRENT STATUS AND FUTURE PERSPECTIVES

Reviewer code: 02446358

Science editor: Wen, Ling-Ling

Date sent for review: 2013-10-08 09:12

Date reviewed: 2013-10-27 09:09

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

The review "TREATMENT OPTIONS IN PATIENTS WITH METASTATIC GASTRIC CANCER: CURRENT STATUS AND FUTURE PERSPECTIVES " by Ahmet nicely summarizes new developments in the treatment of gastric cancer. In particular, systemic chemotherapy and targeted therapies for metastatic gastric cancer in the first- and second-line setting are summarized. I believe it provides an accurate and unbiased view of the current status of this field. Therefore, I would just like to mention some extra info that could be included in the manuscript: In the Second-line chemotherapy, I would include the Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. EVE did improve PFS, but did not significantly improve OS in AGC previously treated with 1 or 2 lines of chemotherapy (J Clin Oncol. 2013 Sep 16. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study.). Secondly, It would be better to include the Randomized phase III trial of irinotecan plus cisplatin versus irinotecan alone after S-1 based chemotherapy failure for patients with advanced and recurrent gastric cancer in the second-line chemotherapy – Japan (Ken S. et al, 2013 ASCO GI Abstrct)



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6171

Title: TREATMENT OPTIONS IN PATIENTS WITH METASTATIC GASTRIC CANCER: CURRENT STATUS AND FUTURE PERSPECTIVES

Reviewer code: 02544512

Science editor: Wen, Ling-Ling

Date sent for review: 2013-10-08 09:12

Date reviewed: 2013-12-04 05:08

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

1. The abstract and Conclusions sections are very summarized and does not facilitate data reproduction. 2. Another issue to be taken into account is sample size. 3. Due to the importance of this study, I would suggest that the authors re-write the manuscript using an easy English language to be understood by public. 4. Explain how does the treatment agents) act on the on EGFR1 and VEGF?